167 related articles for article (PubMed ID: 16909510)
21. HSV therapy and HIV-1 reduction.
Martinez V; Caumes E
N Engl J Med; 2007 May; 356(22):2323; author reply 2324. PubMed ID: 17538093
[No Abstract] [Full Text] [Related]
22. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
23. Is viral shedding a surrogate marker for transmission of genital herpes? A discussion document.
Griffiths P
Herpes; 2004 Dec; 11(3):66-9. PubMed ID: 15960903
[TBL] [Abstract][Full Text] [Related]
24. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.
Schiffer JT; Magaret A; Selke S; Corey L; Wald A
J Antimicrob Chemother; 2011 Nov; 66(11):2593-600. PubMed ID: 21865349
[TBL] [Abstract][Full Text] [Related]
26. Making the most of episodic antiviral therapy for genital herpes.
Patel R
Sex Health; 2008 Sep; 5(3):213-4. PubMed ID: 18828250
[No Abstract] [Full Text] [Related]
27. Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial.
Yi TJ; Shannon B; Chieza L; Su D; Saunders M; Tharao W; Huibner S; Remis R; Raboud J; Kaul R
J Infect Dis; 2014 Sep; 210(5):708-12. PubMed ID: 24664172
[TBL] [Abstract][Full Text] [Related]
28. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
29. Infection fighters. Valtrex suppresses herpes outbreaks.
TreatmentUpdate; 2003; 15(7):5-6. PubMed ID: 17216868
[No Abstract] [Full Text] [Related]
30. Valacyclovir to reduce transmission of genital herpes simplex virus infection.
Drew WL
J Infect Dis; 2009 Mar; 199(6):916. PubMed ID: 19239344
[No Abstract] [Full Text] [Related]
31. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
Fuchs J; Celum C; Wang J; Hughes J; Sanchez J; Cowan F; Reid S; Delany-Moretlwe S; Corey L; Wald A;
J Infect Dis; 2010 Apr; 201(8):1164-8. PubMed ID: 20214474
[TBL] [Abstract][Full Text] [Related]
32. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
33. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
Celum C; Wald A; Lingappa JR; Magaret AS; Wang RS; Mugo N; Mujugira A; Baeten JM; Mullins JI; Hughes JP; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Stevens W; Campbell MS; Thomas KK; Coombs RW; Morrow R; Whittington WL; McElrath MJ; Barnes L; Ridzon R; Corey L;
N Engl J Med; 2010 Feb; 362(5):427-39. PubMed ID: 20089951
[TBL] [Abstract][Full Text] [Related]
34. Treatment of HSV infection in late pregnancy.
Su CW; McKay B
Am Fam Physician; 2012 Feb; 85(4):390-3. PubMed ID: 22335319
[No Abstract] [Full Text] [Related]
35. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
36. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions.
Kimberlin DW; Baley J; ;
Pediatrics; 2013 Feb; 131(2):383-6. PubMed ID: 23378604
[No Abstract] [Full Text] [Related]
37. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
[TBL] [Abstract][Full Text] [Related]
38. HSV therapy and HIV-1 reduction.
Eisenhut M
N Engl J Med; 2007 May; 356(22):2323-4; author reply 2324. PubMed ID: 17542070
[No Abstract] [Full Text] [Related]
39. Health care seeking among men with genital ulcer disease in South Africa: correlates and relationship to human immunodeficiency virus-1 and herpes simplex virus type 2 detection and shedding.
Leichliter JS; Lewis DA; Sternberg M; Habel MA; Paz-Bailey G
Sex Transm Dis; 2011 Sep; 38(9):865-70. PubMed ID: 21844743
[TBL] [Abstract][Full Text] [Related]
40. Use of antiviral drugs to prevent herpesvirus transmission.
Crumpacker CS
N Engl J Med; 2004 Jan; 350(1):67-8. PubMed ID: 14702430
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
